Target intelligence / Profile preview

T cell receptor alpha joining 34 (TRAJ34)

Target
TRAJ34
Molecular classification
Other (T cell receptor J segment gene); not a protein, receptor, enzyme, transporter, etc.
01

Overview

TRAJ34 encodes the joining region 34 of the T cell receptor alpha (TRA) locus in humans. T cell receptors are heterodimers composed of alpha and beta chains (or delta and gamma in a minor subset). The alpha chain locus is assembled during T cell development by V(D)J recombination, generating immune diversity. The TRAJ34 gene segment is one of many joining (J) segments used to assemble the variable region of the TCR alpha chain, contributing to the antigen-binding site of the receptor. Proper recombination of variable (V), joining (J), and constant (C) segments is essential for generating functional T cell receptors capable of antigen recognition in the adaptive immune response. The TRAJ34 gene segment does not encode a protein on its own, but is incorporated into TCRs expressed on T cell surfaces, which are critical for recognizing peptide antigens presented by MHC molecules and mediating immunological responses. In summary, TRAJ34 is not a standalone protein, receptor, or conventional drug target, but a genetic segment integral to generating the diversity of antigen-specific T cell receptors.

Other names
TRAJ34T cell receptor alpha joining 34
02

Mechanism of action

null

03

Biological functions

Antigen recognition (as part of the assembled TCR alpha chain)Immune response (via T cell function)
04

Disease associations

Other (Genetic recombination defects or abnormal T cell receptor diversity can be related to immune deficiency or autoimmunity, but TRAJ34-specific disease associations are not known)

Beyond the preview

Go deeper on T cell receptor alpha joining 34 (TRAJ34).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T cell receptor alpha joining 34 (TRAJ34).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call